Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 Net Cash per Share is $-19.65 as of Feb. 2026. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $51.97 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 146 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks worse than 684930.82% on this metric.
The historical rank and industry rank for COSMOS Pharmaceutical's Net Cash per Share or its related term are showing as below:
CSMYF's Price-to-Net-Cash is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 7.385 * Ranked among companies with meaningful Price-to-Net-Cash only.
COSMOS Pharmaceutical (OTCPK:CSMYF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
COSMOS Pharmaceutical Net Cash per Share Related Terms
COSMOS Pharmaceutical Net Cash per Share Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical Net Cash per Share Competitor Comparison
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Price-to-Net-Cash vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Price-to-Net-Cash falls into.
COSMOS Pharmaceutical Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
COSMOS Pharmaceutical's Net Cash per Share for the fiscal year that ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a Net Cash per Share of $-19.65 as of Feb. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on COSMOS Pharmaceutical and its competitors. According to the industry distribution chart, COSMOS Pharmaceutical ranks #999999 out of 146 companies in the Healthcare Providers & Services industry.
Is COSMOS Pharmaceutical's Net Cash per Share too high?
COSMOS Pharmaceutical's current Net Cash per Share is $-19.65. Based on the distribution chart, COSMOS Pharmaceutical ranks #999999 out of 146 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Net Cash per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #999999 out of 146 companies for Net Cash per Share. This places COSMOS Pharmaceutical in the lower half of its industry. The industry median Net Cash per Share is 7.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Healthcare Providers & Services company?
The median Net Cash per Share among Healthcare Providers & Services companies is 7.39, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median Net Cash per Share is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current Net Cash per Share is $-19.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.97, compared to a current price of $37.06 — trading 28.7% below its estimated fair value. The current Net Cash per Share is $-19.65. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Net Cash per Share is $-19.65 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.7% below its estimated GF Value™ of $51.97.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
Net Cash per Share: $-19.65
GF Value™: $51.97 vs. price of $37.06 (28.7% below fair value)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
